A detailed history of Brinker Capital Investments, LLC transactions in Mirati Therapeutics, Inc. stock. As of the latest transaction made, Brinker Capital Investments, LLC holds 22,687 shares of MRTX stock, worth $0. This represents 0.02% of its overall portfolio holdings.

Number of Shares
22,687
Previous 16,762 35.35%
Holding current value
$0
Previous $1.17 Million 12.3%
% of portfolio
0.02%
Previous 0.02%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 06, 2023

BUY
$41.27 - $98.62 $244,524 - $584,323
5,925 Added 35.35%
22,687 $1.03 Million
Q3 2022

Nov 01, 2022

BUY
$59.5 - $86.7 $160,174 - $233,396
2,692 Added 19.13%
16,762 $1.17 Million
Q2 2022

Jul 18, 2022

BUY
$39.16 - $88.71 $269,499 - $610,502
6,882 Added 95.74%
14,070 $945,000
Q1 2022

May 16, 2022

BUY
$75.82 - $150.97 $544,994 - $1.09 Million
7,188 New
7,188 $591,000

Others Institutions Holding MRTX

About Mirati Therapeutics, Inc.


  • Ticker MRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,609,800
  • Description
  • Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...
More about MRTX
Track This Portfolio

Track Brinker Capital Investments, LLC Portfolio

Follow Brinker Capital Investments, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Brinker Capital Investments, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Brinker Capital Investments, LLC with notifications on news.